- AU$5.12m
- AU$4.01m
- AU$1.30m
- 39
- 24
- 27
- 21
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 3.05 | ||
| Price to Tang. Book | 3.09 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 3.8 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -87.63% | ||
| Return on Equity | -74.01% | ||
| Operating Margin | -115.32% | ||
Financial Summary
| Year End 30th Jun | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | AU$m | 2.02 | 1.87 | 2.35 | 1.75 | 1.3 | n/a | n/a | -12.31% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
dorsaVi Ltd is an Australia-based company focused on developing motion analysis device technologies for use in clinical applications, elite sports, and occupational health and safety. Its segments include Clinical and Workplace. The Company's products include Workplace Solutions, ViMove+, ViSafe, and Research+. Workplace Solution enables employers to assess risk of injury for employees as well as test the effectiveness of proposed changes to OHS workplace design, equipment or methods based on objective evidence. Its clinical solutions (ViMove, ViMove2 and Professional Suite) provides objective assessment, monitoring outside the clinic and immediate biofeedback. The clinical market is segmented into physical therapy (physiotherapists), hospital in the home, and elite sports. Hospital in the home refers to the remote management of patients by clinicians outside of physical therapy. Elite sports refer to the management and optimization of athletes through objective evidence.
Directors
- Andrew Ronchi CEO
- Troy Di Domenico CFO
- John Kowalczyk CEX
- Daniel Ronchi CTO
- Dave Wildermuth CMO
- Meagan Blackburn OTH
- Mark Heaysman OTH
- Matthew May OTH
- Sarah Riseley OTH
- Muhammad Umer OTH
- Zoe Whyatt OTH
- Brendan Case SEC
- Michael Panaccio NED
- Ashraf Attia NID
- Caroline Elliott NID
- Last Annual
- June 30th, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- February 18th, 2008
- Public Since
- December 11th, 2013
- No. of Employees
- 34
- Sector
- Machinery, Equipment & Components
- Industry
- Industrials
- Exchange
Australian Stock Exchange - SEATS- Shares in Issue
- 731,237,925
- Address
- Unit 3, MELBOURNE, 3167
- Web
- https://www.dorsavi.com/
- Phone
- +61 800367728
- Auditors
- MVAB Assurance
Upcoming Events for DVL
Similar to DVL
1414 Degrees
Australian Stock Exchange - SEATS
Altech Batteries
Australian Stock Exchange - SEATS
Amaero
Australian Stock Exchange - SEATS
AML3D
Australian Stock Exchange - SEATS
Austin Engineering
Australian Stock Exchange - SEATS
FAQ
What is the Dorsavi share price?
As of Today at 20:18 UTC, shares in Dorsavi are trading at AU$0.01. This share price information is delayed by 15 minutes.
How has the Dorsavi share price performed this year?
Shares in Dorsavi last closed at AU$0.01 and the price had moved by -46.15% over the past 365 days. In terms of relative price strength the Dorsavi share price has underperformed the ASX All Ordinaries Index by -48.11% over the past year.
What are the analyst and broker recommendations for Dorsavi?
The overall consensus recommendation for Dorsavi is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Dorsavi dividend yield?
Dorsavi does not currently pay a dividend.
Does Dorsavi pay a dividend?
Dorsavi does not currently pay a dividend.
When does Dorsavi next pay dividends?
Dorsavi does not currently pay a dividend.
How do I buy Dorsavi shares?
To buy shares in Dorsavi you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Dorsavi?
As of the previous close price of AU$0.01, shares in Dorsavi had a market capitalisation of AU$5.12m.
Where are Dorsavi shares listed?
Here are the trading details for Dorsavi:
- Country of listing: Australia
- Exchange: ASX
- Ticker Symbol: DVL
What kind of share is Dorsavi?
Based on an overall assessment of its quality, value and momentum Dorsavi is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Dorsavi share price forecast for 2025?
The analyst consensus target price for shares in Dorsavi is AU$0.40. That is 5614.29% above the last closing price of AU$0.01.
Analysts covering Dorsavi currently have a consensus Earnings Per Share (EPS) forecast of for the next financial year.
Find out moreWhat is the trend in the Dorsavi share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Dorsavi. Over the past six months, its share price has underperformed the ASX All Ordinaries Index by -39.99%.
As of the last closing price of AU$0.01, shares in Dorsavi were trading -37.44% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Dorsavi PE Ratio?
The Dorsavi PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at AU$0.01.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Dorsavi?
Dorsavi's management team is headed by:
- Andrew Ronchi - CEO
- Troy Di Domenico - CFO
- John Kowalczyk - CEX
- Daniel Ronchi - CTO
- Dave Wildermuth - CMO
- Meagan Blackburn - OTH
- Mark Heaysman - OTH
- Matthew May - OTH
- Sarah Riseley - OTH
- Muhammad Umer - OTH
- Zoe Whyatt - OTH
- Brendan Case - SEC
- Michael Panaccio - NED
- Ashraf Attia - NID
- Caroline Elliott - NID